Australian Family's $4M Raises Hope for NF Treatment

After losing two family members to neurofibromatosis and living with the condition herself, Zoe Petropoulos has helped raise over $4 million for research that just paid off in a big way.

Researchers at Melbourne's Florey Institute of Neuroscience and Mental Health have discovered significant differences in the gut microbiome of mice with NF1, a genetic disorder affecting one in 2,500 Australians. The finding could open the door to treatments as accessible as dietary changes or probiotics for the cognitive and behavioral challenges linked to the condition, including autism and ADHD.

The 25-year-old teacher's aide knows the devastating impact of neurofibromatosis firsthand. She's undergone regular scans since doctors discovered a tumor in her sinus cavity at age 12, and later learned she had five more tumors growing undetected throughout her body.

Her family's pain runs even deeper. In 2023, her sister-in-law Liz died from NF3 at just 33, leaving behind a husband and two children. Weeks later, Liz's mother, who also had NF, passed away.

These losses fueled the family's Flicker of Hope Foundation, which has poured millions into NF research projects worldwide. That funding helped support the groundbreaking work at the Florey Institute.

The Ripple Effect

Lead researcher Sonali Reisinger says the implications stretch far beyond neurofibromatosis. The gut-brain connection could reshape how scientists approach treating cognitive and behavioral conditions across the board.

"We might be able to just modulate the diet or give prebiotic or probiotic treatments which are easily tolerated and also cheap and easily available," Reisinger explained. That's a game changer compared to expensive pharmaceutical interventions or invasive procedures.

Professor Anthony Hannan, who led the research team, notes this is the first time anyone has studied gut microbiome connections in NF1. The team is now seeking funding for clinical trials to see if the same microbiome changes occur in humans.

The findings, published in Molecular Psychiatry, add to growing evidence about how our gut health influences brain function. If human trials confirm the connection, millions of people living with NF1-related challenges could access affordable, well-tolerated treatments.

Petropoulos considers herself lucky to have a milder case, but she's spent years raising awareness so others facing worse symptoms might find relief. Her family turned their grief into action, and that action just moved the needle toward hope.

The research offers fresh possibilities for families who've spent years waiting for better options than regular scans and symptom management.